Latest filings (excl ownership)
15-12G
Securities registration termination
20 Mar 23
EFFECT
Notice of effectiveness
17 Mar 23
EFFECT
Notice of effectiveness
17 Mar 23
25-NSE
Exchange delisting
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Mar 23
POS AM
Prospectus update (post-effective amendment)
10 Mar 23
POS AM
Prospectus update (post-effective amendment)
10 Mar 23
SC 13E3/A
Going private transaction (amended)
10 Mar 23
8-K
Sumitovant Biopharma Completes Acquisition of Myovant Sciences
10 Mar 23
8-K
Submission of Matters to a Vote of Security Holders
1 Mar 23
SC 13E3/A
Going private transaction (amended)
16 Feb 23
DEFA14A
Additional proxy soliciting materials
16 Feb 23
CT ORDER
Confidential treatment order
2 Feb 23
DEFA14A
Additional proxy soliciting materials
2 Feb 23
10-Q
2023 Q3
Quarterly report
26 Jan 23
8-K
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
26 Jan 23
SC 13E3/A
Going private transaction (amended)
23 Jan 23
DEFM14A
Proxy related to merger
23 Jan 23
SC 13E3/A
Going private transaction (amended)
6 Jan 23
PRER14A
Preliminary revised proxy
6 Jan 23
CORRESP
Correspondence with SEC
6 Jan 23
UPLOAD
Letter from SEC
21 Dec 22
SC 13E3
Going private transaction
8 Dec 22
PREM14A
Preliminary proxy related to merger
8 Dec 22
10-Q
2022 Q2
Quarterly report
26 Oct 22
8-K
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
26 Oct 22
DEFA14A
Additional proxy soliciting materials
24 Oct 22
DEFA14A
Additional proxy soliciting materials
24 Oct 22
8-K
Entry into a Material Definitive Agreement
24 Oct 22
8-K
Submission of Matters to a Vote of Security Holders
21 Oct 22
8-K
Other Events
3 Oct 22
DEFA14A
Additional proxy soliciting materials
27 Jul 22
DEF 14A
Definitive proxy
27 Jul 22
10-Q
2023 Q1
Quarterly report
27 Jul 22
Latest ownership filings
4
Nancy Valente
10 Mar 23
4
MYRTLE S POTTER
10 Mar 23
4
Lauren Merendino
10 Mar 23
4
Uneek Mehra
10 Mar 23
4
David C Marek
10 Mar 23
SC 13D/A
Sumitomo Chemical Co., Ltd.
10 Mar 23
4
Matthew Lang
10 Mar 23
4
Adele M. Gulfo
10 Mar 23
4
MARK GUINAN
10 Mar 23
4
Terrie Curran
10 Mar 23
4
Ferreira Juan Camilo Arjona
10 Mar 23
4
Change in insider ownership
10 Mar 23
SC 13D/A
Sumitomo Chemical Co., Ltd.
6 Mar 23
4
Change in insider ownership
6 Mar 23
SC 13G
Alpine Global Management, LLC
17 Feb 23
SC 13G/A
BB BIOTECH AG
14 Feb 23
SC 13G/A
JANUS HENDERSON GROUP PLC
9 Feb 23
SC 13G
FIL Ltd
9 Feb 23
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
6 Feb 23
4
Matthew Lang
20 Jan 23
4
Lauren Merendino
20 Jan 23
4
David C Marek
20 Jan 23
4
Ferreira Juan Camilo Arjona
20 Jan 23
4
Ferreira Juan Camilo Arjona
5 Jan 23
4
Matthew Lang
5 Jan 23
4
Uneek Mehra
20 Dec 22
4
Terrie Curran
28 Oct 22
4
MARK GUINAN
28 Oct 22
4
Adele M. Gulfo
28 Oct 22
4
MYRTLE S POTTER
28 Oct 22
4
Nancy Valente
28 Oct 22
SC 13D/A
Sumitomo Chemical Co., Ltd.
24 Oct 22
3
Shigeyuki Nishinaka
21 Oct 22
4
Lauren Merendino
20 Oct 22
4
David C Marek
20 Oct 22
4
Matthew Lang
20 Oct 22
4
Ferreira Juan Camilo Arjona
20 Oct 22
4
Ferreira Juan Camilo Arjona
6 Oct 22
4
Matthew Lang
6 Oct 22
SC 13D/A
Sumitomo Chemical Co., Ltd.
3 Oct 22